Keyphrases
Phase II Clinical Trial
100%
Renal Medullary Carcinoma
100%
Pembrolizumab
100%
Tumor-infiltrating Lymphocytes
33%
Lymphocyte Level
33%
Prospective Evaluation
33%
Advanced Disease
16%
Renal Cell Carcinoma
16%
Advanced or Metastatic
16%
Metastatic Disease
16%
Potential Therapeutics
16%
Molecular Profiling
16%
Clinical Activity
16%
Treatment Initiation
16%
Working Diagnosis
16%
Somatic mutation
16%
Time to Progression
16%
Median Time
16%
Novel Therapeutics
16%
Tumor Tissue
16%
Locally Advanced
16%
Programmed Death-ligand 1 (PD-L1)
16%
Clinical Progression
16%
Rapid Disease Progression
16%
Therapeutic Role
16%
Metagenomic Next-generation Sequencing (mNGS)
16%
Immune Profiling
16%
Immune Checkpoint Inhibitors
16%
PD-L1 Expression
16%
Immune Checkpoint Therapy
16%
Basket Trial
16%
Medicine and Dentistry
Clinical Trial
100%
Medullary Carcinoma
100%
Pembrolizumab
100%
Tumor Infiltrating Lymphocyte
33%
Immunity
33%
Programmed Death-Ligand 1
33%
Next Generation Sequencing
16%
Diseases
16%
Neoplasm
16%
Metastatic Carcinoma
16%
Clear Cell Renal Cell Carcinoma
16%
Disease Exacerbation
16%
Somatic Mutation
16%
Immune Checkpoint Inhibitor
16%
Pharmacology, Toxicology and Pharmaceutical Science
Clinical Trial
100%
Medullary Carcinoma
100%
Pembrolizumab
100%
Neoplasm
50%
Diseases
16%
Metastasis
16%
Renal Cell Carcinoma
16%
Disease Exacerbation
16%
Immune Checkpoint Inhibitor
16%
Immunology and Microbiology
Pembrolizumab
100%
Immunity
60%
Tumor-Infiltrating Lymphocytes
40%
Programmed Death-Ligand 1
40%
Carcinoma Cell
20%
Somatic Mutation
20%
Next Generation Sequencing
20%
Neuroscience
Lambrolizumab
100%
Lymphocyte
40%
Somatics
20%